Brentuximab vedotin with lenalidomide and rituximab is approved by the USFDA for relapsed or refractory large B-cell lymphoma
On February 11, 2025, the Food and Drug Administration authorized the use of brentuximab vedotin (Adcetris, Seagen Inc., a subsidiary of Pfizer) in conjunction with lenalidomide and a rituximab product for adult patients..
Mirdametinib is approved by the USFDA for adult and pediatric patients with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas not amenable to complete resection
On February 11, 2025, the Food and Drug Administration sanctioned mirdametinib (Gomekli, SpringWorks Therapeutics, Inc.), a kinase inhibitor, for adult and pediatric patients aged 2 years and older diagnosed with neurofi..
Treosulfan with fludarabine is approved by the USFDA as a preparative regimen for alloHSCT in adult and pediatric patients with AML or MDS
On January 21, 2025, the Food and Drug Administration sanctioned treosulfan (Grafapex, medac GmbH), an alkylating agent, in conjunction with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell tra..
Fam-trastuzumab deruxtecan-nxki is approved by the USFDA for unresectable or metastatic HR-positive, HER2-low or HER2-ultralow breast cancer
On January 27, 2025, the Food and Drug Administration sanctioned fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for unresectable or metastatic hormone receptor (HR)-positive, HER2-low (IHC 1+ or IHC 2+/I..
Sotorasib with panitumumab is approved by the USFDA for KRAS G12C-mutated colorectal cancer
On January 16, 2025, the Food and Drug Administration sanctioned the use of sotorasib (Lumakras, Amgen Inc.) in conjunction with panitumumab (Vectibix, Amgen Inc.) for adult patients diagnosed with KRAS G12C-mutated meta..
Biotechnology, CAR - T Cell therapy, CAR T-Cell, CAR therapy, China, fund raise, Oricell Therapeutics
Oricell raises additional $45M USD to expand its CAR T-Cell therapy to United States
23rd March 2023: The preclinical and early-stage cancer cell therapies being developed by Shanghai biotech Oricell have received an additional $45 million in funding, the company announced on Tuesday. Following a showing at AS..
M D Anderson
First Global Oncology under MD Anderson Cancer Center provides consultation and referral services for cancer patients
MD Anderson Cancer Center is a global cancer diagnosis and treatment institution. It is a training hospital that countless domestic doctors aspire to. It is also the most hopeful hospital for cancer patients around the world. How..